News

Technology News

Antegrin Thera Clears Equity Venture Investment

Monday, October 5, 2015 5:02:00 AM PDT | VentureDeal
   St. Louis, Missouri  --  Antegrin Therapeutics has received nearly $600,000 in equity venture capital financing, according to an SEC regulatory filing.

Antegrin is developing therapies for fibrotic diseases, which are conditions that involve out-of-control scarring of organs.

The company is initially focusing its efforts on idiopathic pulmonary fibrosis, which it says affects up to 5 million persons worldwide.

Antegrin says that it has identified small molecule compounds with the ability to block the function of five specific integrins, which may be primarily responsible for activating the master regulator of fibrosis.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1